Recent data is indicating Everolimus in combination with a Hormonal therapy as a potential new combination treatment regime for advanced breast cancer patients.
Please click here for related article.
ICORG, through the TRIO 019 study, has this treatment option available (study closed to accrual end of 2011) and we have further new studies planned with our collaborators for late 2012.